FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
FDA批准摘要:阿沙利单抗适用于体重至少40公斤且既往接受过两线全身治疗后出现慢性移植物抗宿主病(GVHD)的成人和儿童患者
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-25-0896
Le, Robert Q; Godder, Kamar; Wang, Jingyan; Collazo, Justin S; Konicki, Robyn; Choe, Moran; Feng, Monica; Przepiorka, Donna; Vallejo, Jonathon; Shah, Ankit; Liu, Jiang; Gehrke, Brenda J; Wilson, Willie; Siegel, Andrea; Wu, Yun; Kuo, Charles Yuan-Chia; Ray, Melissa; Pazdur, Richard; Theoret, Marc R; de Claro, R Angelo